This therapeutic principle extends beyond kOA and TKA to other musculoskeletal conditions plagued by fibrosis, including post-traumatic contractures following ACL reconstruction or high-energy fractures, and potentially even hypertrophic scarring and keloid formation, which share similar TGF-β1-driven pathologies. This evidence concerns the gene TGFB1 and keloid.